Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.
Advertisement

Related Content

The Hype And Hope Of Cancer Stem Cell Therapeutics
AACR’s “Most Likely To Succeed” Anticancer Technologies
AACR’s “Most Likely To Succeed” Anticancer Technologies
Cancer Stem Cell Differentiation In Reverse, Spontaneously
Clinical Trials Moving Forward
Cancer Stem Cells: A New Approach to Treating Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS004486

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel